

CITATION REPORT

List of articles citing

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

DOI: 10.1161/01.hyp.0000124667.34652.1a
Hypertension, 2004, 43, 970-6.

Source: <https://exaly.com/paper-pdf/36527607/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|---|-----|-----------|
| 483 | Angiotensin type-1 receptor blockade increases ACE 2 expression in the heart. <i>Hypertension</i> , 2004 , 43, 943-4 | 8.5 | 11 |
| 482 | Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. <i>Hypertension</i> , 2004 , 44, 903-6 | 8.5 | 142 |
| 481 | Novel angiotensin peptides. 2004 , 61, 2720-7 | | 103 |
| 480 | Renal ACE2 expression in human kidney disease. 2004 , 204, 587-93 | | 190 |
| 479 | New ACEs to the renin-angiotensin system. 2005 , 20, 91-5 | | 36 |
| 478 | Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1-7) in healthy man. 2005 , 23, 597-602 | | 34 |
| 477 | Bibliography Current World Literature. 2005 , 20, 217-243 | | |
| 476 | Myocardial infarction increases ACE2 expression in rat and humans: reply. <i>European Heart Journal</i> , 2005 , 26, 1142-1143 | 9.5 | 1 |
| 475 | Myocardial infarction increases ACE2 expression in rat and humans. <i>European Heart Journal</i> , 2005 , 26, 1141; author reply 1141-3 | 9.5 | 10 |
| 474 | Effects of angiotensin-(1-7) blockade on renal function in rats with enhanced intrarenal Ang II activity. 2005 , 67, 1453-61 | | 31 |
| 473 | Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. 2005 , 68, 2189-96 | | 198 |
| 472 | Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. 2005 , 90, 299-305 | | 30 |
| 471 | Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. 2005 , 90, 783-90 | | 186 |
| 470 | Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. 2005 , 289, H2356-63 | | 185 |
| 469 | Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. 2005 , 289, H1013-9 | | 167 |
| 468 | Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. 2005 , 289, H2281-90 | | 292 |
| 467 | Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. 2005 , 289, H1351-8 | | 68 |

| | | | |
|-----|---|------|------|
| 466 | Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. <i>Circulation</i> , 2005 , 111, 2605-10 | 16.7 | 1135 |
| 465 | Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. 2005 , 280, 39353-62 | | 134 |
| 464 | Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. <i>Hypertension</i> , 2005 , 46, 333-40 | 8.5 | 74 |
| 463 | Myocardial infarction increases ACE2 expression in rat and humans: reply. <i>European Heart Journal</i> , 2005 , 26, 1141-1142 | 9.5 | 5 |
| 462 | Effects of the early administration of losartan on the functional and morphological aspects of postmyocardial infarction ventricular remodeling in rabbits. 2005 , 14, 88-95 | | 5 |
| 461 | Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. 2005 , 26, 1270-7 | | 151 |
| 460 | Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. <i>American Journal of Hypertension</i> , 2005 , 18, 922-9 | 2.3 | 26 |
| 459 | Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. 2005 , 14, 1019-31 | | 105 |
| 458 | Effect of hypertension on angiotensin-(1-7) levels in rats with different angiotensin-I converting enzyme polymorphism. <i>Life Sciences</i> , 2006 , 78, 1535-42 | 6.8 | 11 |
| 457 | Olmесartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. 2006 , 29, 865-74 | | 105 |
| 456 | Interference with the renin-angiotensin system in heart failure. 2006 , 372, 331-4 | | 1 |
| 455 | Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. 2006 , 353, 474-81 | | 93 |
| 454 | ACE2: A novel therapeutic target for cardiovascular diseases. 2006 , 91, 163-98 | | 70 |
| 453 | Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. 2006 , 2, 335-42 | | 13 |
| 452 | Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. <i>Hypertension</i> , 2006 , 47, 996-1002 | 8.5 | 189 |
| 451 | The Renin-Angiotensin System: Emerging Concepts. 2006 , 2, 219-226 | | 2 |
| 450 | The therapeutic potential of Angiotensin-(1-7) as a novel Renin-Angiotensin System mediator. 2006 , 6, 603-9 | | 38 |
| 449 | Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. <i>Hypertension</i> , 2006 , 47, 515-21 | 8.5 | 198 |

| | | | |
|-----|--|-----|-----|
| 448 | New mass spectrometric assay for angiotensin-converting enzyme 2 activity. <i>Hypertension</i> , 2006 , 47, 1010-7 | 8.5 | 60 |
| 447 | Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. <i>Hypertension</i> , 2006 , 48, 572-8 | 8.5 | 213 |
| 446 | Angiotensin-converting enzyme II in the heart and the kidney. 2006 , 98, 463-71 | | 195 |
| 445 | ACE2 of the heart: From angiotensin I to angiotensin (1-7). <i>Cardiovascular Research</i> , 2007 , 73, 463-9 | 9.9 | 178 |
| 444 | The two FACES of the tissue renin-angiotensin systems: implication in cardiovascular diseases. 2007 , 13, 1231-45 | | 48 |
| 443 | Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study. 2007 , 9, 602-9 | | 69 |
| 442 | The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection. 2007 , 3, 57-64 | | 1 |
| 441 | Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. 2007 , 9, 594-601 | | 18 |
| 440 | ACE2: a new target for cardiovascular disease therapeutics. 2007 , 50, 112-9 | | 132 |
| 439 | Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. 2007 , 292, R373-81 | | 280 |
| 438 | Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. <i>Life Sciences</i> , 2007 , 81, 916-23 | 6.8 | 49 |
| 437 | Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. 2007 , 581, 526-34 | | 37 |
| 436 | Liver fibrosis: a balance of ACEs?. 2007 , 113, 109-18 | | 85 |
| 435 | The emerging role of ACE2 in physiology and disease. 2007 , 212, 1-11 | | 282 |
| 434 | Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. 2007 , 25, 162-74 | | 89 |
| 433 | Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. 2008 , 65, 1489-508 | | 81 |
| 432 | Are we poised to target ACE2 for the next generation of antihypertensives?. 2008 , 86, 685-90 | | 23 |
| 431 | New angiotensins. 2008 , 86, 663-71 | | 63 |

| | | | |
|-----|--|-----|-----|
| 430 | Angiotensin-(1-7) as an antihypertensive, antifibrotic target. 2008 , 10, 227-32 | | 32 |
| 429 | Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. 2008 , 275, 6033-42 | | 27 |
| 428 | Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. 2008 , 93, 685-93 | | 94 |
| 427 | Angiotensin-(17) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. 2008 , 93, 570-578 | | 4 |
| 426 | RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2. 2008 , 93, 676-84 | | 28 |
| 425 | Angiotensin-converting enzyme 2 in the brain: properties and future directions. 2008 , 107, 1482-94 | | 222 |
| 424 | Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. 2008 , 23, 1327-38 | | 88 |
| 423 | Renin-angiotensin system revisited. 2008 , 264, 224-36 | | 394 |
| 422 | Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. 2008 , 75, 781-6 | | 80 |
| 421 | AT2 receptors: functional relevance in cardiovascular disease. 2008 , 120, 292-316 | | 195 |
| 420 | [Angiotensin converting enzyme 2 and its emerging role in the regulation of the renin angiotensin system]. 2008 , 131, 230-6 | | 17 |
| 419 | An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling. 2008 , 52, 755-7 | | 13 |
| 418 | Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1-7)3292 rats. 2008 , 2, 341-8 | | 22 |
| 417 | An update on hybrid drugs in cardiovascular drug research. 2008 , 3, 1397-408 | | 3 |
| 416 | Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. 2008 , 93, 570-8 | | 31 |
| 415 | Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. <i>Hypertension</i> , 2008 , 51, 712-8 | 8.5 | 122 |
| 414 | Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. <i>Hypertension</i> , 2008 , 51, 1312-7 | 8.5 | 207 |
| 413 | ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET. 2008 , 2, 233-48 | | 18 |

| | | | |
|-----|--|-----|-----|
| 412 | Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2)27 hypertensive rats. 2008 , 294, H1995-2001 | | 17 |
| 411 | Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. 2008 , 294, R1220-6 | | 136 |
| 410 | MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. 2008 , 295, C1169-74 | | 84 |
| 409 | Regulation of ACE2 in cardiac myocytes and fibroblasts. 2008 , 295, H2373-9 | | 175 |
| 408 | Cardiovascular protection by angiotensin-converting enzyme 2: a new paradigm. 2008 , 4, 175-82 | | 4 |
| 407 | Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. 2008 , 31, 553-9 | | 69 |
| 406 | Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. 2008 , 72, 1346-50 | | 40 |
| 405 | Dynamic changes of the renin-angiotensin and associated systems in the rat after pharmacological and dietary interventions in vivo. 2008 , 35, 330-40 | | 3 |
| 404 | Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. <i>Vascular Health and Risk Management</i> , 2009 , 5, 301-14 | 4-4 | 28 |
| 403 | Cardiovascular effects of losartan and its relevant clinical application. 2009 , 16, 3841-57 | | 21 |
| 402 | Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. 2009 , 3, 103-11 | | 21 |
| 401 | Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. 2009 , 2, 446-55 | | 173 |
| 400 | Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats. 2009 , 24, 219-27 | | 29 |
| 399 | Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. 2009 , 24, 294-300 | | 10 |
| 398 | Cardioprotective effects of granulocyte colony-stimulating factor in angiotensin II-induced cardiac remodelling. 2009 , 36, 262-6 | | 8 |
| 397 | Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. 2009 , 32, 533-6 | | 202 |
| 396 | Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. 2009 , 75, 1184-1193 | | 113 |
| 395 | Collecting Duct Renin: A major player in Angiotensin II-dependent Hypertension. 2009 , 3, 96-104 | | 61 |

| | | | |
|-----|---|-----|-----|
| 394 | Functional Cardiovascular Effects of Angiotensin Peptides: Focus on Atherosclerosis and Hypertension. 2009 , 5, 227-236 | | 3 |
| 393 | Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. 2010 , 28, 1054-64 | | 65 |
| 392 | Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. 2010 , 28, 1471-81 | | 39 |
| 391 | ACE2-angiotensin-(1-7)-Mas axis in renal ischaemia/reperfusion injury in rats. 2010 , 119, 385-94 | | 75 |
| 390 | Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients. 2010 , 25, 195-202 | | 16 |
| 389 | Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. 2010 , 128, 119-28 | | 295 |
| 388 | Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2. 2010 , 245, 100-7 | | 36 |
| 387 | Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. 2010 , 15, 332-41 | | 54 |
| 386 | Menores niveles tisulares de la enzima convertidora de angiotensina I homologa (ECA-2) y angiotensina-(1-9) están asociados a mayor remodelamiento de la pared arterial de ratas hipertensas. 2010 , 29, | | |
| 385 | Novel neurohormonal insights with therapeutic potential in chronic heart failure. 2010 , 6, 361-72 | | 2 |
| 384 | Early life stress sensitizes rats to angiotensin II-induced hypertension and vascular inflammation in adult life. <i>Hypertension</i> , 2010 , 55, 494-9 | 8.5 | 61 |
| 383 | Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. 2010 , 4, 17-25 | | 18 |
| 382 | Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. <i>Hypertension</i> , 2010 , 55, 889-96 | 8.5 | 65 |
| 381 | New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. <i>Hypertension</i> , 2010 , 55, 445-52 | 8.5 | 92 |
| 380 | The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. 2010 , 298, F1297-305 | | 113 |
| 379 | Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. <i>Hypertension</i> , 2010 , 55, 207-13 | 8.5 | 143 |
| 378 | Do angiotensin II type 1 receptor blockers have molecular effects?. 2010 , 33, 105-6 | | 6 |
| 377 | Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). 2010 , 59, 197-233 | | 51 |

| | | |
|-----|--|---------|
| 376 | Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. 2010 , 33, 118-22 | 28 |
| 375 | Regulation of angiotensin converting enzyme II by angiotensin peptides in human cardiofibroblasts. 2010 , 31, 1334-40 | 19 |
| 374 | Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs. 2010 , 162, 73-8 | 27 |
| 373 | Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model. 2010 , 28, 30-7 | 8 |
| 372 | Renin Angiotensin System and Cardiovascular Disease. 2010 , | 2 |
| 371 | Physiology of kidney renin. 2010 , 90, 607-73 | 188 |
| 370 | Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. 2011 , 57, 356-65 | 71 |
| 369 | Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling. 2011 , 146, 364-70 | 33 |
| 368 | Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. 2011 , 51, 542-7 | 51 |
| 367 | Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. 2011 , 7, 1077-92 | 95 |
| 366 | ACE2: more of Ang-(1-7) or less Ang II?. 2011 , 20, 1-6 | 111 |
| 365 | Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. 2011 , 8, 176-83 | 54 |
| 364 | Translational success stories: angiotensin receptor 1 antagonists in heart failure. 2011 , 109, 437-52 | 49 |
| 363 | Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7). <i>Hypertension</i> , 2011 , 58, 182-9 | 8.5 161 |
| 362 | Enhancement of renin and prorenin receptor in collecting duct of Cyp1a1-Ren2 rats may contribute to development and progression of malignant hypertension. 2011 , 300, F581-8 | 36 |
| 361 | High Na intake increases renal angiotensin II levels and reduces expression of the ACE2-AT(2)R-MasR axis in obese Zucker rats. 2012 , 303, F412-9 | 29 |
| 360 | Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges. 2012 , 2012, 823193 | 21 |
| 359 | Novel concept in the mechanism of injury and protection of gastric mucosa: role of renin-angiotensin system and active metabolites of angiotensin. 2012 , 19, 55-62 | 22 |

| | | | |
|-----|---|-----|-----|
| 358 | Myocardial migration by fibroblast progenitor cells is blood pressure dependent in a model of angII myocardial fibrosis. 2012 , 35, 449-56 | | 11 |
| 357 | Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure. 2012 , 9, e141-e148 | | 3 |
| 356 | Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor. 2012 , 46, 850-60 | | 28 |
| 355 | Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. <i>Hypertension</i> , 2012 , 59, 1195-203 | 8.5 | 81 |
| 354 | The cardiac expression of Mas receptor is responsive to different physiological and pathological stimuli. 2012 , 35, 196-201 | | 24 |
| 353 | Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. 2012 , 123, 649-58 | | 102 |
| 352 | Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis. <i>Life Sciences</i> , 2012 , 90, 289-300 | 6.8 | 39 |
| 351 | Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice. 2012 , 38, 54-61 | | 26 |
| 350 | Involvement of Renin-Angiotensin System and Vasoactive Angiotensin-(1?7) Metabolite of Angiotensin II in Gastric Mucosal Injury and Gastroprotection. 2012 , 181-190 | | |
| 349 | Role of ACE2 in diastolic and systolic heart failure. 2012 , 17, 683-91 | | 50 |
| 348 | Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury. 2012 , 97, 89-101 | | 46 |
| 347 | Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. 2012 , 351, 208-19 | | 47 |
| 346 | Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis. 2012 , 291, 139-45 | | 22 |
| 345 | Evolving concepts on regulation and function of renin in distal nephron. 2013 , 465, 121-32 | | 32 |
| 344 | Protective arms of the renin-angiotensin-system in neurological disease. 2013 , 40, 580-8 | | 64 |
| 343 | Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis. 2013 , 46, 53-63 | | 54 |
| 342 | Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. <i>Journal of Endocrinology</i> , 2013 , 216, R1-R17 | 4.7 | 349 |
| 341 | Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. 2013 , 98, 109-22 | | 52 |

| | | | |
|-----|--|-----|----|
| 340 | Angiotensin peptides and nitric oxide in cardiovascular disease. 2013 , 19, 1121-32 | | 34 |
| 339 | Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. <i>Hypertension</i> , 2013 , 62, 746-52 | 8.5 | 84 |
| 338 | Protective effects of angiotensin-(1-7) administered with an angiotensin-receptor blocker in a rat model of chronic kidney disease. 2013 , 18, 761-9 | | 14 |
| 337 | Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. 2013 , 36, 342-8 | | 22 |
| 336 | Glomerular angiotensin-converting enzyme 2 in pediatric IgA nephropathy. 2013 , 38, 355-67 | | 5 |
| 335 | Cardiovascular effects of angiotensin A: a novel peptide of the renin-angiotensin system. 2014 , 15, 480-6 | | 20 |
| 334 | Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems. 2014 , 15, 319-28 | | 49 |
| 333 | Receptor MAS protects mice against hypothermia and mortality induced by endotoxemia. 2014 , 41, 331-6 | | 27 |
| 332 | Emerging biomarkers for heart failure: an update. 2014 , 8, 833-40 | | 4 |
| 331 | Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction. 2014 , 94, 21-8 | | 10 |
| 330 | Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter ^B and Gitelman ^B syndromes, human models of endogenous angiotensin II signaling antagonism. 2014 , 32, 2109-19; discussion 2119 | | 42 |
| 329 | Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial. 2014 , 29, 178-85 | | 6 |
| 328 | Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan. 2014 , 37, 616-20 | | 37 |
| 327 | Role of renin-angiotensin system and metabolites of angiotensin in the mechanism of gastric mucosal protection. 2014 , 19, 90-8 | | 8 |
| 326 | Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. 2014 , 92, 847-58 | | 28 |
| 325 | ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. 2014 , 16, 420 | | 83 |
| 324 | Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. 2015 , 19, 1965-74 | | 78 |
| 323 | Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway. 2015 , 172, 3764-78 | | 37 |

| | | | |
|-----|---|-----|-----|
| 322 | Effects of olmesartan therapy on the expression of lung adrenoceptors in rats with chronic heart failure. 2015 , 16, 6-12 | | |
| 321 | Ang (1-7) is a modulator of the vasoconstrictor actions of Ang I and Ang II. 2015 , 16, 254-9 | | 5 |
| 320 | ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. 2015 , 9, 217-37 | | 97 |
| 319 | ACE2 activity was increased in atherosclerotic plaque by losartan: Possible relation to anti-atherosclerosis. 2015 , 16, 292-300 | | 19 |
| 318 | Continuous angiotensin-(1-7) infusion improves myocardial calcium transient and calcium transient alternans in ischemia-induced cardiac dysfunction rats. 2015 , 467, 645-50 | | 4 |
| 317 | Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. <i>American Journal of Hypertension</i> , 2015 , 28, 15-21 | 2.3 | 174 |
| 316 | Antihypertensive Properties of a Novel Morphologic Derivative (4-tert-butyl-2,6-bis(thiomorpholine-4-ilmethyl)phenol). 2016 , 67, 246-51 | | 3 |
| 315 | Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. 2016 , 67, 503-9 | | 22 |
| 314 | The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. 2016 , 97, 180-90 | | 109 |
| 313 | New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?. 2016 , 241, 1888-1899 | | 16 |
| 312 | Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia. 2016 , 94, 37-49 | | 40 |
| 311 | ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. 2016 , 107, 154-162 | | 141 |
| 310 | Brain renin-angiotensin system in the pathophysiology of cardiovascular diseases. 2017 , 125, 72-90 | | 40 |
| 309 | Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients. 2017 , 32, 584-590 | | 2 |
| 308 | Blunting of cardioprotective actions of estrogen in female rodent heart linked to altered expression of cardiac tissue chymase and ACE2. 2017 , 18, 1470320317722270 | | 25 |
| 307 | Influence of antihypertensive drugs on aortic and coronary effects of Ang-(1-7) in pressure-overloaded rats. 2017 , 50, e5520 | | 3 |
| 306 | Blunting of estrogen modulation of cardiac cellular chymase/RAS activity and function in SHR. 2018 , 233, 3330-3342 | | 12 |
| 305 | Angiotensin receptor blocker irbesartan reduces stress-induced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice. 2018 , 69, 167-179 | | 41 |

| | | | |
|-----|---|-----|-----|
| 304 | The depressor axis of the renin-angiotensin system and brain disorders: a translational approach. 2018 , 132, 1021-1038 | | 30 |
| 303 | The Renin-Angiotensin System and the Heart. 2018 , 43-55 | | 1 |
| 302 | Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGF β <i>International Journal of Molecular Sciences</i> , 2019 , 20, | 6.3 | 6 |
| 301 | Angiotensin-(1-7). 2019 , | | 2 |
| 300 | The antiobese effect of AT1 receptor blockade is augmented in mice lacking Mas. 2019 , 392, 865-877 | | 4 |
| 299 | Activation of the Human Angiotensin-(1-12)-Chymase Pathway in Rats With Human Angiotensinogen Gene Transcripts. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 163 | 5.4 | 13 |
| 298 | Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin Pathways as Novel Upstream Targets Regulating Aldosterone. 2019 , | | 1 |
| 297 | Molecular Signaling Mechanisms of the Renin-Angiotensin System in Heart Failure. 2020 , 76-90.e4 | | 0 |
| 296 | Hypertensive urgencies and emergencies: Misconceptions and pitfalls. 2020 , 71, 15-17 | | 5 |
| 295 | Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. <i>Hypertension</i> , 2020 , 76, 1526-1536 | 8.5 | 26 |
| 294 | [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study]. 2020 , 69, 247-254 | | 5 |
| 293 | Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. <i>Hypertension</i> , 2020 , 76, 1753-1761 | 8.5 | 7 |
| 292 | The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. 2020 , 179, 85-100 | | 47 |
| 291 | Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2. 2020 , 887, 173545 | | 23 |
| 290 | COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. 2020 , 17, 543-558 | | 560 |
| 289 | Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. 2020 , 5, 871-883 | | 26 |
| 288 | The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. <i>Life Sciences</i> , 2020 , 257, 118075 | 6.8 | 57 |
| 287 | Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. 2020 , 12, 895-908 | | 50 |

| | | | |
|-----|---|-----|-----|
| 286 | Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. 2020 , 180, 1345-1355 | | 604 |
| 285 | Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney. <i>European Heart Journal</i> , 2020 , 41, 4580-4588 | 9.5 | 22 |
| 284 | Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection. 2020 , 21, 1470320320972018 | | 3 |
| 283 | [COVID-19 and the kidneys]. 2020 , 15, 1-5 | | 1 |
| 282 | Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 8 |
| 281 | Patients taking angiotensin-converting enzyme inhibitors/angiotensin II type I receptor blockers: higher risks of severe acute respiratory syndrome coronavirus 2 infection but milder clinical manifestations?. 2020 , 133, 2650-2652 | | 0 |
| 280 | Sistema renina-angiotensina-aldosterona y COVID19. Implicaciones clínicas. 2020 , 20, 27-32 | | 0 |
| 279 | Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. 2020 , 28, 683-699 | | 17 |
| 278 | COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. 2020 , 153, 193-197 | | 0 |
| 277 | Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients. 2020 , 18, 475-485 | | 3 |
| 276 | COVID-19 and cardiovascular diseases. 2020 , 76, 453-458 | | 35 |
| 275 | Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. 2020 , 43, 1028-1046 | | 65 |
| 274 | Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management. 2020 , 8, 9-19 | | 69 |
| 273 | Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application. 2020 , 56, | | 24 |
| 272 | Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19. 2021 , 39, 6842-6851 | | 21 |
| 271 | COVID-19 and diabetes mellitus: how one pandemic worsens the other. 2020 , 21, 451-463 | | 41 |
| 270 | Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019. 2020 , 598, 4181-4195 | | 3 |
| 269 | The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. <i>Life Sciences</i> , 2020 , 257, 118142 | 6.8 | 11 |

| | | |
|-----|--|-----|
| 268 | ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. 2020 , 7, 588618 | 49 |
| 267 | Mica Can Alleviate TNBS-Induced Colitis in Mice by Reducing Angiotensin II and IL-17A and Increasing Angiotensin-Converting Enzyme 2, Angiotensin 1-7, and IL-10. 2020 , 2020, 3070345 | |
| 266 | Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. 2020 , 113, 797-810 | 1 |
| 265 | COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?. 2020 , 196, 143-151 | 41 |
| 264 | Is Sex a Determinant of COVID-19 Infection? Truth or Myth?. 2020 , 22, 62 | 12 |
| 263 | Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?. 2020 , 9, | 11 |
| 262 | Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis. 2020 , 20, 571-590 | 21 |
| 261 | Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review. 2020 , 10, e040644 | 15 |
| 260 | Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. 2020 , 22, 1780-1788 | 13 |
| 259 | Pharmacological rationale for antihypertensive drug choice on COVID-19-affected patients: ACEI/ARB might not increase their susceptibility. 2020 , 24, 12879-12881 | 1 |
| 258 | Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study. 2021 , 35, 588-597 | 13 |
| 257 | Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. 2020 , 10, 20250 | 14 |
| 256 | Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. 2020 , 6, 96 | 50 |
| 255 | Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways. 2020 , 2020, 8896536 | 5 |
| 254 | The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment. 2021 , 35, 828-836 | 1 |
| 253 | Novel Evidence of Acute Kidney Injury in COVID-19. 2020 , 9, | 18 |
| 252 | Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. 2020 , 127, 104392 | 84 |
| 251 | Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). 2020 , 5, 1020-1026 | 267 |

| | | | |
|-----|--|-----|-----|
| 250 | ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. <i>Hypertension</i> , 2020 , 76, 16-22 | 8.5 | 65 |
| 249 | Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). 2020 , 251, 228-248 | | 473 |
| 248 | Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. 2020 , 9, | | 83 |
| 247 | Focus on Receptors for Coronaviruses with Special Reference to Angiotensin- Converting Enzyme 2 as a Potential Drug Target - A Perspective. 2020 , 20, 807-811 | | 116 |
| 246 | Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. 2020 , 9, | | 285 |
| 245 | COVID-19: ACE2centric Infective Disease?. <i>Hypertension</i> , 2020 , 76, 294-299 | 8.5 | 39 |
| 244 | Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. <i>Life Sciences</i> , 2020 , 256, 117905 | 6.8 | 77 |
| 243 | Impact of COVID-19 on the Cardiovascular System: A Review. 2020 , 9, | | 31 |
| 242 | COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. 2020 , 22, 957-966 | | 137 |
| 241 | Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. 2020 , 6, 98-105 | | 25 |
| 240 | Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications. 2020 , 1 | | 13 |
| 239 | A call to research: the relationship between SARS-2-CoV, ACE 2 and antihypertensives. 2020 , 114, 165-167 | | 2 |
| 238 | Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. 2020 , 38, 1190-1191 | | 17 |
| 237 | Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. 2020 , 75, 526-529 | | 15 |
| 236 | Vitamin D deficiency and co-morbidities in COVID-19 patients [A fatal relationship?]. 2020 , 20, 10-21 | | 55 |
| 235 | ACE2, Much More Than Just a Receptor for SARS-COV-2. 2020 , 10, 317 | | 144 |
| 234 | COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. 2020 , 32, 1599-1608 | | 138 |
| 233 | Key Strategies for Clinical Management and Improvement of Healthcare Services for Cardiovascular Disease and Diabetes Patients in the Coronavirus (COVID-19) Settings: Recommendations From the REPROGRAM Consortium. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 112 | 5.4 | 25 |

| | | | |
|-----|--|------|------|
| 232 | Angiotensin-[1-7] attenuates kidney injury in experimental Alport syndrome. 2020 , 10, 4225 | | 14 |
| 231 | COVID-19 and Cardiovascular Disease. <i>Circulation</i> , 2020 , 141, 1648-1655 | 16.7 | 963 |
| 230 | Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. 2020 , 144, 213-221 | | 181 |
| 229 | Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. 2020 , 382, 1653-1659 | | 1316 |
| 228 | Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of the American Heart Association</i> , 2020 , 9, e016219 | 6 | 292 |
| 227 | A close-up on COVID-19 and cardiovascular diseases. 2020 , 30, 1057-1060 | | 34 |
| 226 | Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. 2020 , 81, 537-540 | | 513 |
| 225 | Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. 2020 , 22, 44 | | 5 |
| 224 | Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019. 2021 , 73, e4197-e4205 | | 212 |
| 223 | Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2 Overexpression, Shedding, and Antibody-dependent Enhancement (ADE). 2020 , 75, e1912 | | 44 |
| 222 | [COVID-19 and the kidneys]. 2020 , 15, 1-6 | | 0 |
| 221 | Tenascin-C aggravates ventricular dilatation and angiotensin-converting enzyme activity after myocardial infarction in mice. 2020 , 7, 2113-2122 | | 12 |
| 220 | Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. 2020 , 319, L325-L336 | | 40 |
| 219 | COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. 2020 , 22, 1109-1119 | | 21 |
| 218 | El ambiente, los desplazamientos y el riesgo cardiovascular en la pandemia por COVID-19. 2020 , 27, 160-165 | | 1 |
| 217 | Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. <i>PLoS ONE</i> , 2020 , 15, e0235248 | 3.7 | 54 |
| 216 | ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System. 2020 , 9, | | 19 |
| 215 | Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. 2020 , 27, 404-411 | | 10 |

| | | | |
|-----|---|-----|-----|
| 214 | Considerations for people with diabetes during the Coronavirus Disease (COVID-19) pandemic. 2020 , 166, 108296 | | 11 |
| 213 | Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature. 2020 , 37, 3450-3462 | | 5 |
| 212 | Angiotensin-(1-7) Attenuates Protein O-GlcNAcylation in the Retina by EPAC/Rap1-Dependent Inhibition of O-GlcNAc Transferase. 2020 , 61, 24 | | 9 |
| 211 | COVID-19 and RAS: Unravelling an Unclear Relationship. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 42 |
| 210 | SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. 2020 , 144, 47-53 | | 86 |
| 209 | COVID-19 and the RAAS-a potential role for angiotensin II?. 2020 , 24, 136 | | 58 |
| 208 | Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. 2020 , 20, 217-221 | | 20 |
| 207 | Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. 2020 , 95, 1222-1230 | | 94 |
| 206 | The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease. <i>Cardiovascular Research</i> , 2020 , 116, 1932-1936 | 9.9 | 41 |
| 205 | Speculation is not evidence: antihypertensive therapy and COVID-19. 2020 , 6, 133-134 | | 17 |
| 204 | Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?. 2020 , 38, 781-782 | | 192 |
| 203 | Mechanisms by which angiotensin-receptor blockers increase ACE2 levels. 2020 , 17, 378 | | 22 |
| 202 | Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. 2020 , 43, 648-654 | | 222 |
| 201 | Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?. 2020 , 168, 105996 | | 91 |
| 200 | Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?. 2020 , 6, 248-251 | | 18 |
| 199 | Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week. 2020 , 75, 3085-3095 | | 90 |
| 198 | Renin-angiotensin-aldosterone system and COVID-19 infection. 2020 , 81, 63-67 | | 45 |
| 197 | Current status of potential therapeutic candidates for the COVID-19 crisis. 2020 , 87, 59-73 | | 163 |

| | | | |
|-----|--|-----|------|
| 196 | The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. 2020 , 76, 14-20 | | 652 |
| 195 | Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. <i>Cardiovascular Research</i> , 2020 , 116, 1688-1699 | 9.9 | 200 |
| 194 | Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications. 2020 , 318, H1080-H1083 | | 28 |
| 193 | Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. 2020 , 126, 1456-1474 | | 1012 |
| 192 | Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. 2021 , 62, 13-23 | | 19 |
| 191 | Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. 2021 , 77, 482-491 | | 30 |
| 190 | Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?. 2021 , 17, 275-284 | | 3 |
| 189 | Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. 2021 , 40, 5-53 | | 13 |
| 188 | Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?. 2021 , 9, 15-22 | | 10 |
| 187 | Renin-angiotensin system at the interface of COVID-19 infection. 2021 , 890, 173656 | | 12 |
| 186 | Double trouble: combined cardiovascular effects of particulate matter exposure and coronavirus disease 2019. <i>Cardiovascular Research</i> , 2021 , 117, 85-95 | 9.9 | 7 |
| 185 | Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. 2021 , 11, 1-12 | | 40 |
| 184 | A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. 2021 , 221, 107750 | | 16 |
| 183 | Renin-angiotensin system inhibitors and mortality in patients with COVID-19. 2021 , 49, 287-294 | | 10 |
| 182 | Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. 2021 , 320, L301-L330 | | 11 |
| 181 | Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2475-2492 | 3.8 | 11 |
| 180 | Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. 2021 , 3, e98-e114 | | 52 |
| 179 | Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. 2021 , 20, 49-59 | | 12 |

| | | |
|-----|---|--------|
| 178 | Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI). 2021 , 361, 287-296 | 13 |
| 177 | Cardiometabolic vigilance in COVID-19 and resource husbandry in resource-challenged times: Clinical practice- based expert opinion. 2021 , 15, 55-62 | |
| 176 | Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview. 2021 , 81, 111016 | 40 |
| 175 | The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection. 2021 , 160, 39-46 | 40 |
| 174 | Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19. 2021 , 72, 122-130 | 13 |
| 173 | Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review. 2021 , 3, 28-40 | 3 |
| 172 | Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure. 2021 , 26, 371-380 | 11 |
| 171 | The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. 2021 , 26, 961-971 | 2 |
| 170 | Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities. 2021 , 22, 1387-1401 | 17 |
| 169 | COVID-19 and cardiovascular disease: Clinical implications of biochemical pathways. 2021 , 7, 97 | 1 |
| 168 | COVID-19 in Patients with Hypertension. 2021 , 1318, 243-261 | 0 |
| 167 | The eye as the discrete but defensible portal of coronavirus infection. 2021 , 19, 176-182 | 32 |
| 166 | Therapy with RAS inhibitors during the COVID-19 pandemic. 2021 , 22, 329-334 | 4 |
| 165 | ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <i>European Heart Journal</i> , 2021 , | 9.5 28 |
| 164 | ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease. 2021 , 135, 387-407 | 13 |
| 163 | Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. 2021 , 135, 1-17 | 11 |
| 162 | Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis. 2021 , 76, 479-486 | 4 |
| 161 | An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. 2021 , 8, 630209 | 6 |

| | | | |
|-----|--|-----|----|
| 160 | The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. 2021 , 58, 831-843 | | 19 |
| 159 | Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. 2021 , 11, 110 | | 2 |
| 158 | Impact of coronavirus disease 2019 on diabetic patients: An endocrinological perspective for better management. 2, 85-91 | | |
| 157 | Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities. 2021 , 34, 187-198 | | 1 |
| 156 | Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic. 2021 , 12, 624052 | | 8 |
| 155 | Potential mechanisms of cerebrovascular diseases in COVID-19 patients. <i>Journal of NeuroVirology</i> , 2021 , 27, 35-51 | 3.9 | 11 |
| 154 | CT visual quantitative evaluation of hypertensive patients with coronavirus disease (COVID-19): Potential influence of angiotensin converting enzyme inhibitors / angiotensin receptor blockers on severity of lung involvement. 2021 , 43, 341-348 | | |
| 153 | Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. <i>Frontiers in Immunology</i> , 2020 , 11, 616595 | 8.4 | 8 |
| 152 | Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. 2021 , 15, 510 | | 1 |
| 151 | Prior Exposure to Angiotensin II Receptor Blockers in Patients With Septic Shock to Individualize Mean Arterial Pressure Target? A Post Hoc Analysis of the Sepsis and Mean Arterial Pressure (SEPSISPAM) Trial. 2021 , 49, e412-e422 | | 2 |
| 150 | A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice. 2021 , 35, e21419 | | 3 |
| 149 | Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms. 2021 , 74, 1740-1751 | | 10 |
| 148 | Determining available strategies for prevention and therapy: Exploring COVID-19 from the perspective of ACE2 (Review). 2021 , 47, | | 3 |
| 147 | SARS-CoV-2 [The Hidden Agonist of the Pressor Arm Within the Renin-Angiotensin System: Considerations for Statins and Propionate Derivatives. 2021 , 1, 131-138 | | |
| 146 | Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: Potential implication for COVID-19 disease. 2021 , 25, 3840-3855 | | 9 |
| 145 | COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention. 2021 , 19, 1083-1092 | | 4 |
| 144 | Cellular Therapy as Promising Choice of Treatment for COVID-19. | | |
| 143 | Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies. 2021 , 12, 619524 | | 9 |

| | | | |
|-----|--|-----|-----|
| 142 | Renal Manifestations of Covid-19: Physiology and Pathophysiology. 2021 , 10, | | 9 |
| 141 | Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis. 2021 , 11, 5012 | | 8 |
| 140 | Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019. 2021 , 36, 247-262 | | 1 |
| 139 | Dual role for angiotensin-converting enzyme 2 in Severe Acute Respiratory Syndrome Coronavirus 2 infection and cardiac fat. 2021 , 22, e13225 | | 3 |
| 138 | Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea. <i>PLoS ONE</i> , 2021 , 16, e0248058 | 3-7 | 3 |
| 137 | Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies. 2021 , 44, 955-968 | | 6 |
| 136 | Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. 2021 , 9, 275-284 | | 116 |
| 135 | The Effect of Chronic and Inhospital Exposure to Renin-Angiotensin System Inhibitors on the Outcome and Inflammatory State of Coronavirus Disease 2019 Adult Inpatients. 2021 , 2021, 5517441 | | 0 |
| 134 | Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19. 2021 , 8, 620990 | | 5 |
| 133 | COVID-19 PANDEMİSİNİN KARDİOVASKÜLER ETKİLERİ | | |
| 132 | Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury. 2021 , 8, ofab170 | | 1 |
| 131 | Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. 2021 , 153, 72-85 | | 7 |
| 130 | Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. <i>PLoS ONE</i> , 2021 , 16, e0248080 | 3-7 | 6 |
| 129 | Human cell receptors: potential drug targets to combat COVID-19. 2021 , 53, 813-842 | | 6 |
| 128 | SARS-CoV-2 Mediated Hyperferritinemia and Cardiac Arrest: Preliminary Insights. 2021 , 26, 1265-1274 | | 1 |
| 127 | Identification of key genes in calcific aortic valve disease via weighted gene co-expression network analysis. 2021 , 14, 135 | | 0 |
| 126 | Association between ACE2 and TMPRSS2 nasopharyngeal expression and COVID-19 respiratory distress. 2021 , 11, 9658 | | 16 |
| 125 | Role of ACE2 polymorphism in COVID-19: impact of age. 2021 , | | 2 |

| | | |
|-----|---|-------|
| 124 | Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity. 2021 , 137, 111363 | 18 |
| 123 | Calcium channel blockers improve prognosis of patients with coronavirus disease 2019 and hypertension. 2021 , 134, 1602-1609 | 9 |
| 122 | Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19. 2021 , 27, 11 | 0 |
| 121 | A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency. 2021 , 12, 684610 | 5 |
| 120 | Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19. 2021 , 320, R925-R937 | 4 |
| 119 | Role of ACE 2 and Vitamin D: The Two Players in Global Fight against COVID-19 Pandemic. | |
| 118 | New perspectives on angiotensin-converting enzyme 2 and its related diseases. 2021 , 12, 839-854 | 1 |
| 117 | Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model. 2021 , 529, 111263 | 2 |
| 116 | Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells. 2021 , 11, 639177 | 3 |
| 115 | A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. 2021 , 37, 100957 | 21 |
| 114 | Using models to advance medicine: mathematical modeling of post-myocardial infarction left ventricular remodeling. 2021 , 1-10 | |
| 113 | RAAS, ACE2 and COVID-19; a mechanistic review. 2021 , 28, 6465-6470 | 2 |
| 112 | Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19. <i>Journal of the American Heart Association</i> , 2021 , 10, e021154 | 6 4 |
| 111 | COVID-19 and metabolic comorbidities: An update on emerging evidences for optimal therapies. 2021 , 140, 111685 | 3 |
| 110 | Characterization of ACE Inhibitors and ATR Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model. 2021 , 11, | 2 |
| 109 | The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. 2021 , 93, 28-34 | 7 |
| 108 | The Crosstalk between SARS-CoV-2 Infection and the RAA System in Essential Hypertension-Analyses Using Systems Approach. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 0 |
| 107 | Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium. 2021 , 11, e053393 | 0 |

| | | |
|-----|--|----|
| 106 | Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. 2021 , 52, 250-260 | 7 |
| 105 | Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. 2021 , 12, 20420986211011345 | 4 |
| 104 | Angiotensin Converting Enzyme 2: A Critical Regulator of the Renin-Angiotensin System. 2006 , 129-142 | 1 |
| 103 | Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy. 2014 , 259-289 | 4 |
| 102 | Angiotensin-(1-7) and the Heart. 2019 , 83-104 | 1 |
| 101 | Differential Diagnosis and Possible Therapeutics for Coronavirus Disease 2019. 2020 , 51-71 | 1 |
| 100 | [Acute renal failure in COVID-19]. 2020 , 16, 1-4 | 1 |
| 99 | Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORY dlstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease. 2020 , 226, 60-68 | 9 |
| 98 | Drug repurposing and cytokine management in response to COVID-19: A review. 2020 , 88, 106947 | 24 |
| 97 | Drugs acting on renin angiotensin system and use in ill patients with COVID-19. 2020 , 75, 319-325 | 4 |
| 96 | Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system?. 2020 , 43, 854-856 | 53 |
| 95 | ACE2 as a potential therapeutic target for pandemic COVID-19.. 2020 , 10, 39808-39813 | 14 |
| 94 | ACE2 in the renin-angiotensin system. 2020 , 134, 3063-3078 | 7 |
| 93 | Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease. 2020 , 134, 2645-2664 | 6 |
| 92 | Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis. 2020 , Publish Ahead of Print, | 1 |
| 91 | Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension. | 13 |
| 90 | Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcome of COVID-19 : A Systematic Review and Meta-analysis. | 5 |
| 89 | The Association Between the Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of Covid-19 Confirmed Cases and Deaths in the United States: Geospatial Study. 2020 , | 2 |

| | | | |
|----|---|-----|-----|
| 88 | Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study. 2020 , | | 9 |
| 87 | RAAS blockade, kidney disease, and expression of ACE2, the entry receptor for SARS-CoV-2, in kidney epithelial and endothelial cells. | | 5 |
| 86 | Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study. | | 2 |
| 85 | What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19. 2020 , 34, e13991 | | 1 |
| 84 | Cardiovascular disease, heart failure and COVID-19. 2020 , 21, 1470320320926903 | | 7 |
| 83 | Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy. <i>PLoS ONE</i> , 2013 , 8, e66082 | 3.7 | 44 |
| 82 | Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia. <i>PLoS ONE</i> , 2020 , 15, e0244349 | 3.7 | 6 |
| 81 | Cardiovascular Implications of COVID-19 Infections. <i>Methodist DeBaakey Cardiovascular Journal</i> , 2020 , 16, 146-154 | 2.1 | 8 |
| 80 | Influence of AT1 blockers on obesity and stress induced eating of cafeteria diet. <i>Journal of Endocrinology</i> , 2018 , | 4.7 | 4 |
| 79 | [Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers]. <i>Kardiologiya</i> , 2020 , 60, 4-9 | 1.5 | 4 |
| 78 | Valsartan in the treatment of heart attack survivors. <i>Vascular Health and Risk Management</i> , 2006 , 2, 125-134 | 4.4 | 19 |
| 77 | Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?. <i>Minerva Cardioangiologica</i> , 2020 , 68, 339-346 | 1.1 | 0 |
| 76 | Updates of Cardiovascular Manifestations in COVID-19: Korean Experience to Broaden Worldwide Perspectives. <i>Korean Circulation Journal</i> , 2020 , 50, 543-554 | 2.2 | 11 |
| 75 | Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study. <i>Epidemiology and Health</i> , 2021 , 43, e2021004 | 5.6 | 7 |
| 74 | A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). <i>Cureus</i> , 2020 , 12, e7560 | 1.2 | 243 |
| 73 | Are the Newest Angiotensin Receptor Blockers Preferred than the Old Members in COVID-19 Patients with Cardiovascular Comorbidity?. <i>International Journal of Pharmacology</i> , 2021 , 17, 435-441 | 0.7 | |
| 72 | Progression of knowledge in diabetes mellitus and covid-19. <i>International Journal of Clinical Biochemistry and Research</i> , 2021 , 8, 163-168 | 1 | |
| 71 | Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. <i>GeroScience</i> , 2021 , 43, 2289-2304 | 8.9 | 5 |

| | | | |
|----|--|-----|----|
| 70 | Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-8 | 4 | 2 |
| 69 | Review: Roles of human serum albumin in prediction, diagnoses and treatment of COVID-19. <i>International Journal of Biological Macromolecules</i> , 2021 , 193, 948-955 | 7.9 | 15 |
| 68 | Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes. <i>Frontiers in Endocrinology</i> , 2021 , 12, 731974 | 5.7 | 6 |
| 67 | Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex. <i>In Silico Pharmacology</i> , 2021 , 9, 55 | 4.3 | 3 |
| 66 | COVID-19 hastalarında anjiyotensin 2 (ACE2) genin ekspresyon seviyesi. <i>Cukurova Medical Journal</i> , 2021 , 46, 1508-1515 | 0.1 | |
| 65 | Regulation of Cardiovascular Control Mechanisms by Angiotensin-(1 α) and Angiotensin-Converting Enzyme 2. 2007 , 43-59 | | 1 |
| 64 | Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin. 2009 , 112-159 | | |
| 63 | Newer Insights into the Biochemical Physiology of the Renin-Angiotensin System: Role of Angiotensin-(1-7), Angiotensin Converting Enzyme 2, and Angiotensin-(1-12). 2009 , 7-17 | | |
| 62 | The Renin-Angiotensin System and the Heart. 2009 , 181-188 | | 0 |
| 61 | Collecting Duct Renin: A Critical Link in Angiotensin II-Dependent Hypertension. 2009 , 133-141 | | 0 |
| 60 | Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System. 2010 , 121-133 | | |
| 59 | Antihypertensive Drugs and Their Cardioprotective and Renoprotective Roles in the Prevention and Management of Cardiovascular Disease. 2011 , 161-181 | | |
| 58 | Blocker, angiotensin II receptor olmesartan to interrupt cardiovascular continuum: vessels and cardioprotective, anti-atherosclerotic and metabolic pleiotropic effects (part 2). <i>Cardiosomatics</i> , 2015 , 6, 65-74 | 0.4 | |
| 57 | Association Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in Hospitalized Patients. <i>Chinese Medical Sciences Journal</i> , 2021 , 36, 17-26 | 1.3 | 0 |
| 56 | The role of pre-existing chronic disease in cardiac complications from SARS-CoV-2 infection: A systematic review and meta-analysis. | | |
| 55 | Whey-Derived Peptides at the Heart of the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 0 |
| 54 | The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities. <i>Molecules</i> , 2020 , 26, | 4.8 | 0 |
| 53 | Biología del SARS-CoV-2. <i>Revista Mexicana De Trasplantes</i> , 2020 , 9, 139-148 | 0.1 | |

| | | | |
|----|--|-----|----|
| 52 | A brand-new cardiorenal syndrome in the COVID-19 'setting. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 291-296 | 4.6 | 12 |
| 51 | Neurological manifestations of coronavirus infections, before and after COVID-19: a review of animal studies. <i>Journal of NeuroVirology</i> , 2021 , 1 | 3.9 | 0 |
| 50 | Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 5 |
| 49 | Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation. <i>Chemico-Biological Interactions</i> , 2021 , 351, 109738 | 5 | 4 |
| 48 | The Role of Endothelium in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 3 |
| 47 | A Comprehensive review on genomic diversity and epidemiology of COVID-19. <i>International Journal of Clinical Virology</i> , 2020 , 4, 081-095 | 0.7 | |
| 46 | Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients. | | 0 |
| 45 | Implications of renal ACE2 expression in the age of COVID-19. <i>European Heart Journal</i> , 2020 , 41, 4589-4594 | 5.4 | 2 |
| 44 | Positive association of Angiotensin II Receptor Blockers, not Angiotensin-Converting Enzyme Inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia. | | |
| 43 | RAAS blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. | | |
| 42 | Cessation of Renin-Angiotensin System Antagonists During the SARS-CoV-2 Pandemic [Do We Have the Evidence?]. <i>Journal of Interdisciplinary Medicine</i> , 2020 , 5, 105-109 | 0.2 | |
| 41 | Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. <i>Vascular Health and Risk Management</i> , 2007 , 3, 125-37 | 4.4 | 71 |
| 40 | Increased Incidence, Morbidity, and Mortality in Human Coronavirus NL63 Associated with ACE Inhibitor Therapy and Implication in SARS-CoV-2 (COVID-19). <i>Missouri Medicine</i> , 2020 , 117, 346-354 | 0.8 | 2 |
| 39 | Cardiovascular Manifestations of COVID-19. <i>Heart Views</i> , 2020 , 21, 171-186 | 0.7 | 3 |
| 38 | COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021 , 1, 233-258 | | 1 |
| 37 | Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry.. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, | 4.2 | 3 |
| 36 | COVID-19: Invasion, pathogenesis and possible cure - A review.. <i>Journal of Virological Methods</i> , 2022 , 300, 114434 | 2.6 | 2 |
| 35 | Angiotensin-Converting-Enzyme 2 and SARS-CoV2: A Dangerous Liaison. <i>Timisoara Medical Journal</i> , 2020 , 2020, 1 | 0 | |

| | | | |
|----|---|------|---|
| 34 | Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial.. <i>Trials</i> , 2022 , 23, 36 | 2.8 | 0 |
| 33 | COVID MED [An Early Pandemic Randomized Clinical Trial of Losartan for Hospitalized COVID-19 Patients. | | |
| 32 | Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids.. <i>IScience</i> , 2022 , 25, 103818 | 6.1 | 0 |
| 31 | Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.. <i>American Journal of Hypertension</i> , 2022 , 35, 462-469 | 2.3 | 1 |
| 30 | The Effects of AT1R Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice.. <i>Journal of Cardiovascular Translational Research</i> , 2022 , 15, 38 | 3.3 | 1 |
| 29 | Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases.. <i>Molecules</i> , 2022 , 27, | 4.8 | 2 |
| 28 | Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials.. <i>British Journal of Clinical Pharmacology</i> , 2022 , | 3.8 | 0 |
| 27 | Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target.. <i>Biomedicines</i> , 2022 , 10, | 4.8 | 6 |
| 26 | Genetic Landscape of the ACE2 Coronavirus Receptor.. <i>Circulation</i> , 2022 , | 16.7 | 0 |
| 25 | ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2021 , | 9.9 | 3 |
| 24 | Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. <i>Journal of the American Heart Association</i> , 2021 , e023535 | 6 | 3 |
| 23 | Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.. <i>Drugs</i> , 2021 , 82, 43 | 12.1 | 1 |
| 22 | Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells.. <i>International Journal of Molecular Sciences</i> , 2022 , 23, | 6.3 | 0 |
| 21 | Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs.. <i>Blood Pressure</i> , 2022 , 31, 80-90 | 1.7 | 0 |
| 20 | From COVID-19 to Sarcoidosis: How Similar Are These Two Diseases?. <i>Frontiers in Immunology</i> , 2022 , 13, | 8.4 | 1 |
| 19 | Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research. <i>Journal of the American Heart Association</i> , | 6 | 1 |
| 18 | Evaluation of Drugs and Strategies for Treating Coronary Artery Ectasia: Update and Future Perspective. <i>Jundishapur Journal of Chronic Disease Care</i> , 2022 , In Press, | 1.4 | |
| 17 | The prevalence and course of COVID-19 and the Cardiovascular Diseases. <i>Heart Vessels and Transplantation</i> , | | |

| | | | |
|----|--|-----|---|
| 16 | Cardiorenal Syndrome in COVID-19 Patients: A Systematic Review. <i>Frontiers in Cardiovascular Medicine</i> , 9, | 5.4 | 0 |
| 15 | The Effect of Renin-Angiotensin Blockers on COVID-19 Related Mortality: A Tertiary Center's Experience. <i>Cor Et Vasa</i> , 2022, 64, 277-281 | 0.3 | |
| 14 | Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure. <i>Life Sciences</i> , 2022, 305, 120757 | 6.8 | 1 |
| 13 | COVIDMED – An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients. <i>Contemporary Clinical Trials Communications</i> , 2022, 100968 | 1.8 | 1 |
| 12 | Sex Difference in MasR Expression and Functions in the Renal System. 2022, 2022, 1-10 | | 0 |
| 11 | Advances in Targeting ACE2 for Developing COVID-19 Therapeutics. | | 1 |
| 10 | O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease. 2022, 11, 3637 | | 1 |
| 9 | Is the prognosis of non-hypertensive, COVID-19 patients treated with renin-angiotensin-aldosterone system inhibitors more uncertain?. 2022, 10, | | 0 |
| 8 | Angiotensin-converting enzyme 2 in human plasma and lung tissue. 2023, 32, 6-15 | | 0 |
| 7 | Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep Immunophenotyping. 2022, 2022, | | 1 |
| 6 | Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19. 2023, 18, e0280280 | | 1 |
| 5 | Unveiling the prevalence and impact of diabetes on COVID-19. 2023, 287-301 | | 0 |
| 4 | Angiotensin II Type 1 Receptor Blocker Prevents Abdominal Aortic Aneurysm Progression in Osteoprotegerin-Deficient Mice via Upregulation of Angiotensin (17). 2023, 12, | | 0 |
| 3 | Morphological aspect of the angiotensin-converting enzyme 2. 2023, 389-417 | | 0 |
| 2 | Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure. 2023, 15, 1820 | | 0 |
| 1 | Coronavirus 19 (COVID-19) and Syndrome of Inappropriate Anti-Diuretic Hormone Secretion (SIADH): A Review of Literature. | | 0 |